Please ensure Javascript is enabled for purposes of website accessibility

HEXO Shares Slump 27% on Second-Quarter Results

By Eric Volkman - Mar 30, 2020 at 5:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Impairment charges left the cannabis company's bottom line well in the red.

HEXO's (HEXO 1.23%) week is not starting off well. On Monday, the cannabis products maker released its results for the second quarter of its fiscal 2020, and the market responded by selling off its stock.

For the quarter, the Ottawa-based company booked net revenue of 17 million Canadian dollars ($12.1 million), 17% higher than in Q1. On the bottom line, its net loss narrowed to slightly over CA$298 million ($213 million); the previous quarter's deficit was more than CA$364 million ($260 million). On a per-share basis, the Q2 net loss amounted to CA$1.13 ($0.80).

Marijuana bud with Canadian flag in the background.

Image source: Getty Images

The majority of its shortfall was caused by a pair of impairments. The company booked a charge of more than CA$138 million ($99 million) on its Niagara growth facility, which is currently up for sale, and took nearly CA$112 million ($80 million) in goodwill impairment charges.

As for operational metrics, the company produced 22,305 kilos of product, up substantially from the first-quarter tally of 16,107. However the average selling price for HEXO's recreational marijuana -- far and away the bulk of its sales -- fell to CA$3.49 ($2.49) per gram or gram equivalent; in Q1, that number was CA$4.35 ($3.11).

As is typical among companies now, with the SARS-CoV-2 coronavirus pandemic causing massive economic uncertainty, HEXO did not provide guidance either for its current quarter or its fiscal year.

Investors, who have grown weary of the bottom-line losses frequently reported by marijuana companies, did not react positively to HEXO's latest fundamentals. The company's shares fell by almost 28% on Monday, a day when the major stock market indexes rose by more than 3%.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

HEXO Stock Quote
$0.21 (1.23%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.